Clinical Trials Logo
  1. Home
  2. Hodgkin Lymphoma
  3. NCT03469921
  4. Details
NCT03469921 Clinical Trial

Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016

Hodgkin Lymphoma Clinical Trial

— HEMAJA  

Official title:
Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT03469921
Other study ID # HEMAJA-IPC 2017-045
Secondary ID
Status Completed
Phase
First received March 5, 2018
Last updated March 16, 2018
Start date January 1, 2000
Est. completion date December 31, 2016

Study information
Verified date March 2018
Source Institut Paoli-Calmettes
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Unicentric retrospective analysis of a cohort of 602 young adult and adolescent patients, aged 15 to 30 years, with haematological malignancies, and managed between 2000 and 2016

Description:

The therapeutic results (response and survival) of young adult and adolescent patients with hematological malignancies are generally lower than those usually observed in adults over the age of 30, with equivalent treatment, particularly in lymphomatous pathology.The overall analysis of this large cohort of patients in its entirety, then by age groups (15-17 years, 18-25 years, 26-30 years) and pathology aims to describe the future of patients and patients. compare them to the results of the literature observed in this age group, and according to the therapeutic regimens administered (pediatric regimen or adult regimen).

Recruitment information / eligibility
Status Completed
Enrollment 602
Est. completion date December 31, 2016
Est. primary completion date December 31, 2016
Accepts healthy volunteers
Gender All
Age group 15 Years to 30 Years
Eligibility Inclusion Criteria:

- Malignant hemopathies (acute leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma) in primary care between 2000 and 2016.

Exclusion Criteria:

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• administered therapeutic regimens
administered therapeutic regimens

Locations
Country Name City State
France Institut Paoli Calmettes Marseille Bouches Du Rhone

Sponsors (1)
Lead Sponsor Collaborator
Institut Paoli-Calmettes

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Global Survival delay between the date of diagnosis and the date of the latest news 15 years
Primary Survival without event delay between the date of diagnosis and an event (relapse, death, lost of follow-up) 15 years
Primary Progression-free survival defined as the delay between the date of diagnosis and the date of relapse or death. 15 years
Secondary Epidemiological distribution by pathology compared to the adult population over 30 years Epidemiological distribution by pathology compared to the adult population over 30 years 1 day
Secondary Descriptive analysis of the characteristics of the disease at diagnosis by pathology Descriptive analysis of the characteristics of the disease at diagnosis by pathology 15 years
Secondary Descriptive analysis of treatments by pathology Descriptive analysis of treatments by pathology 15 years
Secondary Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology Overall survival (OS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology 15 years
Secondary Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology Event-free survival (EFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology 15 years
Secondary Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology Progression-free survival (PFS) of patients included in clinical trials compared to patients not included for the overall cohort and pathology 15 years
Secondary Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology. Long-term toxicity analysis (second cancers, fertility) for the global cohort and pathology. 15 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05019976 - Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma N/A
Active, not recruiting NCT03617666 - Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Recruiting NCT02507479 - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Phase 2
Active, not recruiting NCT02191930 - Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma Phase 2
Completed NCT01943682 - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Phase 1
Completed NCT01393106 - Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma Phase 2
Terminated NCT00992030 - R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma Phase 3
Terminated NCT00722865 - Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma Phase 2
Unknown status NCT00598624 - Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT03242902 - To Decrease Fatigue With Light Therapy Phase 3
Active, not recruiting NCT05205512 - Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial N/A
Recruiting NCT03681561 - Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma Phase 1/Phase 2
Recruiting NCT03250962 - SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma Phase 2
Recruiting NCT04510610 - Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Phase 2/Phase 3
Completed NCT06295211 - Brentuximab Vedotin Combined With Bendamustine Supercharge, a Low-toxicity and Efficient Salvage Regimen for Primary Refractory or First-relapsed Classic Hodgkin Lymphoma: Long-term Results of a Retrospective Monocenter Study.
Active, not recruiting NCT02256137 - A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer
Completed NCT02432235 - Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma Phase 1